|

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • Hebei Senlang Biotechnology Inc., Ltd.1

Indications

  • 19 and 20+ B Cell Hematologic Tumors1
  • 19 and 22+ B Cell Hematologic Tumors1
  • Cancer1

Other1 trial

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.